Stock Details
4523.T is Eisai Co., Ltd.'s stock. Stock exchange Tokyo (Currency JPY). Average price in 50 days is 5,699.64๏ฟฅ. Average daily volumn in 3 months 887.03k. Market cap 1.53T



Stock symbol : 4523.T. Exchange : Tokyo. Currency : JPY
Lastest price : 5,272.00๏ฟฅ. Total volume : 1.12M. Market state PREPRE
Click reload if you want to check the lastest price on market!!!

Eisai Co., Ltd. (4523.T)
Last Price
5,272.00๏ฟฅ
Change
-52.00
Volume
1.12M

Previous Close5,324.00
Open5,324.00
Day Range5,266.00-5,369.00
Bid0.00 x N/A
Ask0.00 x N/A
Volume1.12M
Average Volume887.03k
Market Cap1.53T
Beta0.47
52 Week Range5,266.00-12,765.00
Trailing P/E31.52
Foward P/E24.92
Dividend (Yield %)3.03%
Ex-Dividend Date2022-09-29



Financial Details


According to Eisai Co., Ltd.'s financial reports the company's revenue in 2022 were 756.23B an increase( +17.21%) over the years 2021 revenue that were of 645.94B. In 2022 the company's total earnings were 47.95B while total earnings in 2021 were 42.12B( +11.9%).


Loading ...



Organization

Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted... medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.

eisai-co-ltd-logo

Market Cap:
1.53T
Revenue:
756.23B
Total Assets:
1.24T
Total Cash:
309.63B


News about "Eisai Co., Ltd."

Eisai Co., Ltd. (ESALF) CEO Haruo Naito on Q4 2022 Results - Earnings Call Transcript

Source from : Seeking Alpha - 13 days ago

Q4 2022 Earnings Conference Call May 13, 2022 3:30 AM ET Company Participants Haruo Naito - CEO Ivan Cheung - Senior VP & President of Neurology ...See details»


Eisai Co Ltd - Stock Sustainability ESALF

Source from : Morningstar%2c Inc. - 3 days ago

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.See details»


eisai-otcmktsesaly-releases-fy-2023-earnings-guidance-image

Eisai (OTCMKTS:ESALY) Releases FY 2023 Earnings Guidance

Source from : ETF Daily News - 13 days ago

About Eisai (Get Rating) Eisai Co, Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of ...See details»


Eisai Co. Ltd. ADR

Source from : Wall Street Journal - 3 days ago

1 Day ESALY 2.85% DJIA 1.98% S&P 500 1.86% Health Care/Life Sciences -0.42% ...See details»


Eisai Co Ltd - Stock Trailing Returns ESALF

Source from : Morningstar%2c Inc. - 4 days ago

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...See details»


Epilepsy Drug Market Size | SWOT Analysis and Key Development with Top Players Pfizer, Eisai Co., Ltd

Source from : Digital Journal - 1 days ago

A new report titled โ€œGlobal Epilepsy Drug Market Professional Report 2020-2026โ€ has been added by Straits Research to its repository of research reports. The report analyzes and estimates the ...See details»


Eisai Co., Ltd. (4523)

Source from : Investing.com - 25 days ago

ยฉ 2007-2022 Fusion Media Limited. All Rights Reserved. Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the ...See details»


Eisai Co., Ltd. (ESALY)

Source from : Yahoo Finance - 23 days ago

Stocks jump after Fed raises rates by 50 basis points, but Powell pushes back on bigger hikes: Dow adds 932 points, or 2.8%, Nasdaq gains 3.2% ...See details»


Eisai - Biogen Seek Accelerated Approval For Their Second Alzheimer's Drug

Source from : Yahoo Finance - 16 days ago

Eisai Co Ltd (OTC: ESALY) has completed the rolling submission of the FDA marketing application under the accelerated approval for lecanemab (BAN2401) for mild cognitive impairment (MCI ...See details»


Biogen CEO to leave as Alzheimer's drug struggles

Source from : Reuters - 23 days ago

March, 2014: Eisai Co Ltd (4523.T) agrees to collaborate with Biogen to develop treatments for Alzheimer's disease, including an option for the Tokyo-based company to jointly develop and ...See details»


Eisai initiates preparation for NDA of ultrahigh-dose mecobalamin for ALS in Japan

Source from : Pharmabiz - 15 days ago

Eisai Co., Ltd. announced that it has initiated preparation on a New Drug Application for ultrahigh-dose mecobalamin (development code: E0302) for amyotrophic lateral sclerosis (ALS) in Japan, based ...See details»


Client Profile: Eisai Co Ltd

Source from : OpenSecrets.org - 16 days ago

Feel free to distribute or cite this material, but please credit OpenSecrets. For permission to reprint for commercial uses, such as textbooks, contact OpenSecrets: info[at]crp.org ...See details»


eisai-vietnam-opens-new-office-and-enters-strategic-partnership-image

Eisai Vietnam opens new office and enters strategic partnership

Source from : Vietnam Investment Reviev - 12 days ago

Eisai Vietnam announced the opening of its new office and signed a four-year cooperation relationship with the Vietnam Association of Neurology.See details»


Glioblastoma Multiforme Treatment (GBM) Market Trends, Growth by 2022, Prominent Key Players, Future Demand, Size and Forecast Estimation by 2028

Source from : Digital Journal - 2 days ago

The Glioblastoma Multiforme Treatment (GBM) Market Demand Analysis offers a comprehensive analysis of the various features, demand, product developments, revenue generation, and sales of the ...See details»